spacer
home > pmps > spring 2011 > maximising effectiveness of dpi capsules
PAY PER VIEW SERVICE

 

Dear guest!

article: Maximising Effectiveness of DPI Capsules
format: Adobe Acrobat PDF file
cost: £

spacer

Industry Events

INTERPHEX 2020

15-17 July 2020, Javits Center NYC


More info >>

 
News and Press Releases

TAGRISSOTM (osimertinib) DEMONSTRATED UNPRECEDENTED DISEASE-FREE SURVIVAL IN THE ADJUVANT TREATMENT OF STAGE IB-IIIA COMPLETELY RESECTED PATIENTS WITH EGFR MUTATION

Detailed results from the Phase III ADAURA trial showed AstraZeneca’s Tagrisso (osimertinib) demonstrated a statistically significant and clinically meaningful improvement in disease-free survival (DFS) in the adjuvant treatment of patients with early-stage (IB, II and IIIA) epidermal growth factor receptor-mutated (EGFRm) non-small cell lung cancer (NSCLC) after complete tumour resection with curative intent.
More info >>

 
©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement